Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
INBRX-106 by Inhibrx for Oral Cavity (Mouth) Cancer: Likelihood of Approval
INBRX-106 is under clinical development by Inhibrx and currently in Phase III for Oral Cavity (Mouth) Cancer. According to GlobalData,...
INBRX-106 by Inhibrx for Oropharyngeal Cancer: Likelihood of Approval
INBRX-106 is under clinical development by Inhibrx and currently in Phase III for Oropharyngeal Cancer. According to GlobalData, Phase III...
INBRX-106 by Inhibrx for Laryngeal Cancer: Likelihood of Approval
INBRX-106 is under clinical development by Inhibrx and currently in Phase III for Laryngeal Cancer. According to GlobalData, Phase III...
INBRX-106 by Inhibrx for Hypopharyngeal Cancer: Likelihood of Approval
INBRX-106 is under clinical development by Inhibrx and currently in Phase III for Hypopharyngeal Cancer. According to GlobalData, Phase III...
INBRX-106 by Inhibrx for Triple-Negative Breast Cancer (TNBC): Likelihood of Approval
INBRX-106 is under clinical development by Inhibrx and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData,...
INBRX-106 by Inhibrx for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
INBRX-106 is under clinical development by Inhibrx and currently in Phase II for Head And Neck Squamous Cell Carcinoma (HNSC)....
INBRX-106 by Inhibrx for Gastrointestinal Stromal Tumor (GIST): Likelihood of Approval
INBRX-106 is under clinical development by Inhibrx and currently in Phase II for Gastrointestinal Stromal Tumor (GIST). According to GlobalData,...